IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
A randomised phase II double-blinded placebo-controlled trial designed to explore the utility
of immunotherapy for patients with acute psychosis associated with anti-neuronal membranes
(NMDA-receptor or Voltage Gated Potassium Channel).
Primary objective: To test the efficacy of immunotherapy (IVIG and rituximab) for patients
with acute psychosis associated with anti-neuronal membranes.
Secondary objective: To test safety of immunotherapy (IVIG and rituximab) for patients with
acute psychosis associated with anti-neuronal membranes.